A Response to: Letter to the Editor Regarding “Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 Vaccination”

Documenti analoghi

• Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial
  di: Juleen Gayed, et al.
  Pubblicazione: (2024-07-01)
• Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial
  di: Juleen Gayed, et al.
  Pubblicazione: (2024-01-01)
• Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial
  di: Oyeniyi Diya, et al.
  Pubblicazione: (2025-07-01)
• A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults
  di: Angela Branche, et al.
  Pubblicazione: (2025-04-01)
• A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18–64 Years of Age (Preliminary Results)
  di: Rucha Dadhe, et al.
  Pubblicazione: (2026-04-01)